Total Payments
$2.2M
2024 Payments
$225,085
Companies
33
Transactions
1,620
Medicare Patients
2,917
Medicare Billing
$137,523
Payment Breakdown by Category
Consulting$960,867 (44.4%)
Other$547,117 (25.3%)
Research$437,069 (20.2%)
Travel$206,788 (9.6%)
Food & Beverage$10,204 (0.5%)
Education$189.94 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $960,867 | 249 | 44.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $439,135 | 124 | 20.3% |
| Unspecified | $437,069 | 588 | 20.2% |
| Travel and Lodging | $206,788 | 356 | 9.6% |
| Honoraria | $87,487 | 28 | 4.0% |
| Grant | $18,350 | 2 | 0.8% |
| Food and Beverage | $10,204 | 269 | 0.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,145 | 1 | 0.1% |
| Education | $189.94 | 3 | 0.0% |
Payments by Type
General
$1.7M
1,032 transactions
Research
$437,069
588 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $377,916 | 229 | $0 (2024) |
| GENZYME CORPORATION | $374,449 | 144 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $371,287 | 445 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $269,497 | 97 | $0 (2024) |
| Eli Lilly and Company | $186,797 | 113 | $0 (2024) |
| LEO Pharma AS | $145,393 | 163 | $0 (2024) |
| ABBVIE INC. | $84,913 | 132 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $83,213 | 48 | $0 (2022) |
| Incyte Corporation | $50,138 | 78 | $0 (2024) |
| LEO Pharma Inc. | $42,678 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $225,085 | 229 | GENZYME CORPORATION ($68,450) |
| 2023 | $217,784 | 187 | GENZYME CORPORATION ($85,495) |
| 2022 | $254,176 | 228 | Regeneron Pharmaceuticals, Inc. ($53,007) |
| 2021 | $292,565 | 177 | PFIZER INC. ($79,900) |
| 2020 | $280,756 | 135 | PFIZER INC. ($75,963) |
| 2019 | $267,007 | 308 | Eli Lilly and Company ($50,779) |
| 2018 | $395,441 | 223 | GENZYME CORPORATION ($107,010) |
| 2017 | $229,422 | 133 | Regeneron Pharmaceuticals, Inc. ($89,768) |
All Payment Transactions
1,620 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 12/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 12/06/2024 | Amgen Inc. | Enbrel (Biological) | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,820.00 | General |
| Category: Immunology | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $1,135.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $956.50 | Research |
| Study: A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $525.08 | Research |
| Study: A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,250.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | — | In-kind items and services | $500.00 | Research |
| Study: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis • Category: Immunology | ||||||
| 11/04/2024 | Amgen Inc. | Enbrel (Biological) | Consulting Fee | Cash or cash equivalent | $3,484.87 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $3,301.02 | General |
| 11/04/2024 | LEO Pharma AS | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,853.16 | General |
| 11/04/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,481.28 | General |
| 11/04/2024 | Amgen Inc. | Enbrel (Biological) | Travel and Lodging | Cash or cash equivalent | $446.09 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $422.56 | General |
| 11/04/2024 | LEO Pharma AS | — | Travel and Lodging | Cash or cash equivalent | $237.22 | General |
| 11/04/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $189.61 | General |
| 11/04/2024 | Amgen Inc. | Enbrel (Biological) | Travel and Lodging | Cash or cash equivalent | $28.02 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $26.54 | General |
| 11/04/2024 | LEO Pharma AS | — | Travel and Lodging | Cash or cash equivalent | $14.90 | General |
| 11/04/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $11.91 | General |
| 11/04/2024 | Amgen Inc. | Enbrel (Biological) | Travel and Lodging | Cash or cash equivalent | $10.83 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $9.48 | General |
| 11/04/2024 | LEO Pharma AS | — | Travel and Lodging | Cash or cash equivalent | $5.32 | General |
| 11/04/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $4.63 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $126,889 | 182 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $108,590 | 104 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $22,403 | 44 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $18,704 | 31 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $16,811 | 30 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $14,715 | 23 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $14,628 | 27 |
| HEALTH ECONOMICS OUTCOME RESEARCH RELATED TO DUPIXENT | Regeneron Pharmaceuticals, Inc. | $10,332 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $10,123 | 8 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $9,836 | 8 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $8,252 | 10 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | Regeneron Pharmaceuticals, Inc. | $7,023 | 13 |
| An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients greater than or equal to 6 to less than 18 Years of Age With Atopic Dermatitis | GENZYME CORPORATION | $5,250 | 14 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | $4,050 | 1 |
| M16-048 | AbbVie, Inc. | $4,050 | 1 |
| CC-10004-AD-001 - A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Celgene Corporation | $4,022 | 1 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $3,974 | 4 |
| JAK INHIBITOR DERM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,860 | 3 |
| Dupixent Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $3,480 | 5 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $3,153 | 6 |
| Epidemiology and patient reported outcomes in paediatric patients with atopic dermatitis | GENZYME CORPORATION | $2,750 | 5 |
| TRALOKINUMAB MONOTHERAPY FOR MODERATE TO SEVERE ATOPIC DERMATITIS - ECZTRA 2 ECZEMA TRALOKINUMAB TRIAL NO. 2 ECZTRA 2 | LEO Pharma AS | $2,500 | 1 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $2,327 | 4 |
| A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged >=6 Months to < 6 Years With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $2,250 | 6 |
| CIBINQO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,416 | 2 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab | Regeneron Pharmaceuticals, Inc. | $1,174 | 2 |
| A Phase 23 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged 6 Months to 6 Years With Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,089 | 10 |
| SLR - Burden of Atopic Dermatitis in Pediatric Patients and their Caregivers: A Systematic Literature Review (Pediatric Burden MS) | SANOFI-AVENTIS U.S. LLC | $1,015 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab | SANOFI-AVENTIS U.S. LLC | $1,002 | 2 |
| Design, Validation and Scoring of the Atopic Dermatitis Control Tool (ADCT) | SANOFI-AVENTIS U.S. LLC | $972.40 | 2 |
| A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Dupilumab Administered to Adult Patients With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Are Intolerant to Oral Cyclosporine A, or When This Treatment is Not Medically Advisable | Regeneron Pharmaceuticals, Inc. | $922.29 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Mo | SANOFI-AVENTIS U.S. LLC | $875.79 | 1 |
| AD-1334: Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1); AD-1416: Study of Dupilumab (REGN668/SAR231893) Monothera | SANOFI-AVENTIS U.S. LLC | $875.79 | 2 |
| LIBERTY-AD CHRONOS | SANOFI-AVENTIS U.S. LLC | $865.00 | 1 |
| SOLO 1; SOLO 2 | SANOFI-AVENTIS U.S. LLC | $784.65 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $750.00 | 2 |
| A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | SANOFI-AVENTIS U.S. LLC | $730.91 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $500.00 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, >=6 Years to <12 Years of Age, With Severe Atopic Dermatitis | GENZYME CORPORATION | $500.00 | 1 |
| Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients 6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | GENZYME CORPORATION | $500.00 | 1 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH HEOR | Regeneron Pharmaceuticals, Inc. | $484.62 | 1 |
| SOLO 1; SOLO 2; ADP2b | SANOFI-AVENTIS U.S. LLC | $472.43 | 1 |
| Study of REGN668/SAR231893 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $340.59 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $313.14 | 1 |
| A Phase 2 3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged 6 Months to 6 Years With Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $296.44 | 1 |
| Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (SOLO 1) | SANOFI-AVENTIS U.S. LLC | $289.09 | 1 |
| Epidemiology and patient reported outcomes in paediatric patients with atopic dermatitis | SANOFI US SERVICES INC. | $250.00 | 1 |
| A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $224.40 | 1 |
| Patient-reported Disease Burden in Adults with Atopic Dermatitis in the Clinical Practice Setting and Impact of Inadequately Controlled Disease: A US Cross-sectional Study | SANOFI-AVENTIS U.S. LLC | $184.88 | 2 |
| Epi AWARE | SANOFI-AVENTIS U.S. LLC | $24.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $20.01 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 745 | 1,215 | $192,840 | $38,607 |
| 2022 | 10 | 684 | 1,100 | $158,814 | $33,559 |
| 2021 | 12 | 794 | 1,405 | $171,464 | $37,587 |
| 2020 | 10 | 694 | 1,225 | $134,388 | $27,770 |
Total Patients
2,917
Total Services
4,945
Medicare Billing
$137,523
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 249 | 297 | $56,999 | $14,838 | 26.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 81 | 95 | $26,683 | $6,907 | 25.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 123 | 157 | $30,686 | $6,803 | 22.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 72 | 79 | $24,400 | $1,854 | 7.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 12 | 12 | $10,792 | $1,708 | 15.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $4,476 | $1,163 | 26.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 12 | 12 | $4,614 | $1,114 | 24.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 16 | 21 | $7,042 | $1,031 | 14.6% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 11 | 12 | $5,268 | $772.70 | 14.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 94 | 445 | $9,031 | $740.21 | 8.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 22 | 23 | $2,494 | $664.93 | 26.7% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 16 | 16 | $6,166 | $534.56 | 8.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 18 | 27 | $4,189 | $476.82 | 11.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 236 | 293 | $51,693 | $13,515 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 71 | 86 | $22,588 | $6,230 | 27.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 121 | 154 | $27,956 | $5,809 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $6,872 | $1,885 | 27.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 62 | 70 | $20,155 | $1,592 | 7.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 26 | 26 | $5,688 | $1,583 | 27.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 24 | 25 | $7,968 | $1,193 | 15.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 92 | 388 | $7,159 | $629.88 | 8.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 19 | 23 | $2,196 | $585.59 | 26.7% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 14 | 16 | $6,539 | $536.15 | 8.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 253 | 341 | $52,257 | $16,106 | 30.8% |
| 17000 | Destruction of skin growth | Office | 2021 | 143 | 179 | $31,172 | $6,606 | 21.2% |
About Dr. Eric Simpson, MD
Dr. Eric Simpson, MD is a Dermatology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972511426.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Simpson, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $225,085 received in 2024. These payments were reported across 1,620 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($960,867).
As a Medicare-enrolled provider, Simpson has provided services to 2,917 Medicare beneficiaries, totaling 4,945 services with total Medicare billing of $137,523. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Portland, OR
- Active Since 08/03/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1972511426
Products in Payments
- DUPIXENT (Biological) $483,576
- DUPIXENT (Drug) $297,047
- DUPIXENT DUPILUMAB INJECTION (Biological) $170,541
- CIBINQO (Drug) $99,373
- EUCRISA (Drug) $65,102
- TAPINAROF (Drug) $30,719
- Enbrel (Biological) $18,387
- TREMFYA (Drug) $14,718
- RINVOQ (Biological) $12,723
- VTAMA (Drug) $9,774
- ADBRY (Biological) $8,774
- NO PRODUCT DISCUSSED (Drug) $8,690
- Otezla (Drug) $5,976
- QBREXZA (Drug) $5,600
- TALTZ (Drug) $2,887
- ENSTILAR (Drug) $1,965
- Humira (Biological) $691.61
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Portland
Andrew Blauvelt, Md, MD
Dermatology — Payments: $2.6M
Dermatology $2.6M
Benjamin Ehst, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $1.5M
Dermatology $1.5M
Dr. Jason Hawkes, Md, Ms, MD, MS
Dermatology — Payments: $876,779
Dermatology $876,779
Dr. Omar Qutub, Md, MD
Dermatology — Payments: $73,858
Dermatology $73,858
Alex Ortega Loayza, Md, MD
Dermatology — Payments: $72,824
Dermatology $72,824
Jon Hanifin, Md, MD
Dermatology — Payments: $66,868
Dermatology $66,868